271 related articles for article (PubMed ID: 31415087)
41. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
Rani P; Zehra D; Mansoor M; Rani P
Arch Womens Ment Health; 2024 Mar; ():. PubMed ID: 38478035
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA; Anderson RA; Ballantyne E; Bolognese J; Caetano C; Joffe H; Kerr M; Panay N; Seitz C; Seymore S; Trower M; Zuurman L; Pawsey S
Menopause; 2023 Mar; 30(3):239-246. PubMed ID: 36720081
[TBL] [Abstract][Full Text] [Related]
43. Fezolinetant (Veozah) for menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2023 Jun; 65(1679):97-99. PubMed ID: 37339088
[No Abstract] [Full Text] [Related]
44. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
45. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
46. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
[TBL] [Abstract][Full Text] [Related]
47. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
[TBL] [Abstract][Full Text] [Related]
48. Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms.
Lambert MNT; Thorup AC; Hansen ESS; Jeppesen PB
PLoS One; 2017; 12(6):e0176590. PubMed ID: 28591133
[TBL] [Abstract][Full Text] [Related]
49. Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.
Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
Neuroendocrinology; 2018; 106(2):148-157. PubMed ID: 28380486
[TBL] [Abstract][Full Text] [Related]
50. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
51. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
53. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
54. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review.
Menown SJ; Tello JA
Adv Ther; 2021 Oct; 38(10):5025-5045. PubMed ID: 34514552
[TBL] [Abstract][Full Text] [Related]
55. Neurokinin 3 Receptor Antagonism: A Novel Treatment for Menopausal Hot Flushes.
Modi M; Dhillo WS
Neuroendocrinology; 2019; 109(3):242-248. PubMed ID: 30504731
[TBL] [Abstract][Full Text] [Related]
56. Vasomotor symptoms and neurovegetative comorbidities on the menopause: insights from an Italian quantitative research.
Graziottin A; Banerji V; Hall G
Gynecol Endocrinol; 2019 Sep; 35(9):762-766. PubMed ID: 31266379
[TBL] [Abstract][Full Text] [Related]
57. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial.
Butt DA; Lock M; Lewis JE; Ross S; Moineddin R
Menopause; 2008; 15(2):310-8. PubMed ID: 17917611
[TBL] [Abstract][Full Text] [Related]
58. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial.
Tice JA; Ettinger B; Ensrud K; Wallace R; Blackwell T; Cummings SR
JAMA; 2003 Jul; 290(2):207-14. PubMed ID: 12851275
[TBL] [Abstract][Full Text] [Related]
59. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.
Newton KM; Reed SD; LaCroix AZ; Grothaus LC; Ehrlich K; Guiltinan J
Ann Intern Med; 2006 Dec; 145(12):869-79. PubMed ID: 17179056
[TBL] [Abstract][Full Text] [Related]
60. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
